GILD34:BVMF
Gilead Sciences Inc BDR
65,81 BRL
0,00%
(0,00) 1 D
16. okt., 16:56:00 GMT-3 · BRL
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for GILD34 …
Åpne
66,36 BRL
Høy
66,41 BRL
Lav
65,81 BRL
Markedsverdi
193,67 mrd.
Snittvolum
261,00
Volum
1,78k
52 u høy
67,38 BRL
52 u lav
51,33 BRL
Utestående aksjer
1,24 mrd.
Antall ansatte
17k
Åpne
66,36 BRL
Høy
66,41 BRL
Lav
65,81 BRL
Markedsverdi
193,67 mrd.
Snittvolum
261,00
Volum
1,78k
52 u høy
67,38 BRL
52 u lav
51,33 BRL
Utestående aksjer
1,24 mrd.
Antall ansatte
17k
Nyhetssaker
Fra nettkilder og nyhetspartnere
The Motley Fool
·
for 9 timer siden
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
for 11 timer siden
Gilead Sciences stock trades 0.32 percent above its Xetra close
Simply Wall Street
·
for 1 døgn siden
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
MarketBeat
·
for 1 døgn siden
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Om Gilead Sciences Inc BDR
Administrerende direktørDaniel O'Day
Ansatte17k
Grunnlagt22. juni 1987
HovedkontorFoster City, California, USA
Sektor-
Nettstedgilead.com